
Opinion|Videos|November 26, 2024
Utilizing Antibiotics in Treatment of C Difficile
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI).
- New therapies like fecal microbiota transplantation (FMT) and monoclonal antibodies aim to restore healthy gut flora and provide targeted immune support.
The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the role of antibiotics in the treatment of recurrent C difficile infections?
- Why was it necessary to develop new therapies beyond antibiotics?
Advertisement
Related to this article

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Contributor: Congress Can Bring Mental Health Care to the 21st Century
5


